Predictive value of pre-treatment FDG PET in patients with non-Hodgkin lymphoma treated with radioimmunotherapy: a systematic review

Silvia Morbelli, Selene Capitanio, Luca Guerra, Luigi Rigacci

Research output: Contribution to journalReview article

Abstract

Purpose: We aimed to systematically review studies addressing the value of baseline FDG PET as predictive biomarker for response to RIT in patients with NHL. Methods: We searched (last update: March 2019) the databases PubMed, PMC, Google Scholar and Medline using both as text and as MeSH (Medical Subject Headings) terms the following: “positron emission tomography—PET”, “PET/CT”, “FDG”, “18F-fluorodeoxyglucose”, and “radioimmunotherapy”, ‘90Y-ibritumomab tiuxetan” and “non-Hodgkin lymphoma” and “follicular lymphoma”. Among all the retrieved articles, we selected only those specifically analyzing role, predictive and overall value of pretreatment FDG PET in patients with NHL submitted to RIT. Results: The initial search retrieved seventy articles, however, only eight specifically analyzed the predictive value of pretreatment FDG PET in patients with NHL submitted to RIT and were thus discussed. Eight studies in 254 patients evaluated the role of FDG PET as a predictor of response prior to RIT. Despite several methodological issues, patients- and lesion-based analyses carried out to-date seem to suggest a relevant prognostic role of both morphological computed tomography and metabolic imaging. Conclusions: Although it is still not possible to specifically define the best PET-based predictor (i.e. SUVmax, TLG, MTV), FDG-PET is a promising tool for a more accurate and individualized selection of NHL patients candidates to RIT. The availability of FDG PET examinations in homogenous group of patients included in already completed clinical trials might be used in the next future also to specifically assess the prognostic value of baseline FDG PET in patients treated with RIT based on the study design.

Original languageEnglish
Pages (from-to)159-170
Number of pages12
JournalClinical and Translational Imaging
Volume7
Issue number3
DOIs
Publication statusPublished - Jun 1 2019

Fingerprint

Radioimmunotherapy
Non-Hodgkin's Lymphoma
Therapeutics
Medical Subject Headings
Follicular Lymphoma
Fluorodeoxyglucose F18
PubMed
Patient Selection
Biomarkers
Tomography
Clinical Trials
Databases
Electrons

Keywords

  • F-FDG
  • Y-ibritumomab tiuxetan
  • Positron emission tomography
  • Radioimmunotherapy

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Predictive value of pre-treatment FDG PET in patients with non-Hodgkin lymphoma treated with radioimmunotherapy : a systematic review. / Morbelli, Silvia; Capitanio, Selene; Guerra, Luca; Rigacci, Luigi.

In: Clinical and Translational Imaging, Vol. 7, No. 3, 01.06.2019, p. 159-170.

Research output: Contribution to journalReview article

@article{06801f982d5943a68a90ba5b400c8a82,
title = "Predictive value of pre-treatment FDG PET in patients with non-Hodgkin lymphoma treated with radioimmunotherapy: a systematic review",
abstract = "Purpose: We aimed to systematically review studies addressing the value of baseline FDG PET as predictive biomarker for response to RIT in patients with NHL. Methods: We searched (last update: March 2019) the databases PubMed, PMC, Google Scholar and Medline using both as text and as MeSH (Medical Subject Headings) terms the following: “positron emission tomography—PET”, “PET/CT”, “FDG”, “18F-fluorodeoxyglucose”, and “radioimmunotherapy”, ‘90Y-ibritumomab tiuxetan” and “non-Hodgkin lymphoma” and “follicular lymphoma”. Among all the retrieved articles, we selected only those specifically analyzing role, predictive and overall value of pretreatment FDG PET in patients with NHL submitted to RIT. Results: The initial search retrieved seventy articles, however, only eight specifically analyzed the predictive value of pretreatment FDG PET in patients with NHL submitted to RIT and were thus discussed. Eight studies in 254 patients evaluated the role of FDG PET as a predictor of response prior to RIT. Despite several methodological issues, patients- and lesion-based analyses carried out to-date seem to suggest a relevant prognostic role of both morphological computed tomography and metabolic imaging. Conclusions: Although it is still not possible to specifically define the best PET-based predictor (i.e. SUVmax, TLG, MTV), FDG-PET is a promising tool for a more accurate and individualized selection of NHL patients candidates to RIT. The availability of FDG PET examinations in homogenous group of patients included in already completed clinical trials might be used in the next future also to specifically assess the prognostic value of baseline FDG PET in patients treated with RIT based on the study design.",
keywords = "F-FDG, Y-ibritumomab tiuxetan, Positron emission tomography, Radioimmunotherapy",
author = "Silvia Morbelli and Selene Capitanio and Luca Guerra and Luigi Rigacci",
year = "2019",
month = "6",
day = "1",
doi = "10.1007/s40336-019-00330-7",
language = "English",
volume = "7",
pages = "159--170",
journal = "Clinical and Translational Imaging",
issn = "2281-5872",
publisher = "Springer-Verlag Italia s.r.l.",
number = "3",

}

TY - JOUR

T1 - Predictive value of pre-treatment FDG PET in patients with non-Hodgkin lymphoma treated with radioimmunotherapy

T2 - a systematic review

AU - Morbelli, Silvia

AU - Capitanio, Selene

AU - Guerra, Luca

AU - Rigacci, Luigi

PY - 2019/6/1

Y1 - 2019/6/1

N2 - Purpose: We aimed to systematically review studies addressing the value of baseline FDG PET as predictive biomarker for response to RIT in patients with NHL. Methods: We searched (last update: March 2019) the databases PubMed, PMC, Google Scholar and Medline using both as text and as MeSH (Medical Subject Headings) terms the following: “positron emission tomography—PET”, “PET/CT”, “FDG”, “18F-fluorodeoxyglucose”, and “radioimmunotherapy”, ‘90Y-ibritumomab tiuxetan” and “non-Hodgkin lymphoma” and “follicular lymphoma”. Among all the retrieved articles, we selected only those specifically analyzing role, predictive and overall value of pretreatment FDG PET in patients with NHL submitted to RIT. Results: The initial search retrieved seventy articles, however, only eight specifically analyzed the predictive value of pretreatment FDG PET in patients with NHL submitted to RIT and were thus discussed. Eight studies in 254 patients evaluated the role of FDG PET as a predictor of response prior to RIT. Despite several methodological issues, patients- and lesion-based analyses carried out to-date seem to suggest a relevant prognostic role of both morphological computed tomography and metabolic imaging. Conclusions: Although it is still not possible to specifically define the best PET-based predictor (i.e. SUVmax, TLG, MTV), FDG-PET is a promising tool for a more accurate and individualized selection of NHL patients candidates to RIT. The availability of FDG PET examinations in homogenous group of patients included in already completed clinical trials might be used in the next future also to specifically assess the prognostic value of baseline FDG PET in patients treated with RIT based on the study design.

AB - Purpose: We aimed to systematically review studies addressing the value of baseline FDG PET as predictive biomarker for response to RIT in patients with NHL. Methods: We searched (last update: March 2019) the databases PubMed, PMC, Google Scholar and Medline using both as text and as MeSH (Medical Subject Headings) terms the following: “positron emission tomography—PET”, “PET/CT”, “FDG”, “18F-fluorodeoxyglucose”, and “radioimmunotherapy”, ‘90Y-ibritumomab tiuxetan” and “non-Hodgkin lymphoma” and “follicular lymphoma”. Among all the retrieved articles, we selected only those specifically analyzing role, predictive and overall value of pretreatment FDG PET in patients with NHL submitted to RIT. Results: The initial search retrieved seventy articles, however, only eight specifically analyzed the predictive value of pretreatment FDG PET in patients with NHL submitted to RIT and were thus discussed. Eight studies in 254 patients evaluated the role of FDG PET as a predictor of response prior to RIT. Despite several methodological issues, patients- and lesion-based analyses carried out to-date seem to suggest a relevant prognostic role of both morphological computed tomography and metabolic imaging. Conclusions: Although it is still not possible to specifically define the best PET-based predictor (i.e. SUVmax, TLG, MTV), FDG-PET is a promising tool for a more accurate and individualized selection of NHL patients candidates to RIT. The availability of FDG PET examinations in homogenous group of patients included in already completed clinical trials might be used in the next future also to specifically assess the prognostic value of baseline FDG PET in patients treated with RIT based on the study design.

KW - F-FDG

KW - Y-ibritumomab tiuxetan

KW - Positron emission tomography

KW - Radioimmunotherapy

UR - http://www.scopus.com/inward/record.url?scp=85066985064&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85066985064&partnerID=8YFLogxK

U2 - 10.1007/s40336-019-00330-7

DO - 10.1007/s40336-019-00330-7

M3 - Review article

AN - SCOPUS:85066985064

VL - 7

SP - 159

EP - 170

JO - Clinical and Translational Imaging

JF - Clinical and Translational Imaging

SN - 2281-5872

IS - 3

ER -